Xenobiotic Metabolism – How the Body Processes Foreign Substances

What is Xenobiotic Metabolism?

Xenobiotic metabolism (also called biotransformation) is the set of biochemical processes the human body uses to chemically modify and eliminate foreign substances – known as xenobiotics. The term derives from the Greek words xenos (foreign) and bios (life). Common xenobiotics include pharmaceutical drugs, environmental pollutants, pesticides, food additives, and industrial chemicals.

The primary goal of xenobiotic metabolism is to convert lipophilic (fat-soluble) compounds into more hydrophilic (water-soluble) metabolites that can be excreted via the kidneys or bile. The liver is the central organ of this process, though the intestine, lungs, kidneys, and skin also play important roles.

Phases of Xenobiotic Metabolism

Xenobiotic metabolism is classically divided into three phases:

Phase I – Functionalization Reactions

In Phase I, xenobiotics undergo oxidation, reduction, or hydrolysis reactions that introduce or expose reactive functional groups (e.g., hydroxyl groups). This increases polarity and prepares the molecule for Phase II reactions. The most important enzyme system involved is the cytochrome P450 (CYP) superfamily, a group of monooxygenases predominantly located in the liver.

Phase II – Conjugation Reactions

In Phase II, the reactive groups generated in Phase I are conjugated with endogenous polar molecules to further increase water solubility and reduce biological activity. Key conjugation reactions include:

• Glucuronidation (via UDP-glucuronosyltransferases)
• Sulfation (via sulfotransferases)
• Acetylation (via N-acetyltransferases)
• Glutathione conjugation (via glutathione S-transferases)
• Methylation

The resulting conjugates are generally more water-soluble and pharmacologically less active than the parent compounds.

Phase III – Transport and Excretion

In Phase III, conjugated metabolites are actively transported out of cells by specific transport proteins (e.g., ABC transporters such as P-glycoprotein) and eliminated via urine or bile.

Clinical Significance

Xenobiotic metabolism has major clinical implications:

• Drug interactions: Many drugs are metabolized by the same CYP enzymes. Inhibitors or inducers of these enzymes can significantly alter plasma drug concentrations, leading to toxicity or therapeutic failure.
• Genetic variability: Polymorphisms in metabolizing enzyme genes (e.g., CYP2D6, CYP2C19) result in inter-individual differences in drug metabolism. Patients may be classified as poor metabolizers, intermediate metabolizers, extensive metabolizers, or ultra-rapid metabolizers.
• Toxicology: Some xenobiotics are converted into reactive, toxic, or carcinogenic intermediates during metabolism – a process known as bioactivation. A classic example is the conversion of paracetamol (acetaminophen) to the hepatotoxic metabolite NAPQI in overdose situations.
• Diet and environment: Dietary components such as grapefruit juice can inhibit CYP enzymes and alter drug metabolism in clinically relevant ways.

Organs Involved

While the liver is the primary site of xenobiotic metabolism, other tissues also contribute:

• Small intestine (first-pass metabolism)
• Lungs (inhalation of airborne compounds)
• Kidneys (renal excretion)
• Skin (dermal absorption)
• Placenta (protection of the developing fetus)

Factors Influencing Metabolism

The metabolic capacity for xenobiotics varies widely between individuals and is influenced by:

• Genetics (enzyme polymorphisms)
• Age (reduced enzyme activity in neonates and the elderly)
• Sex
• Diet and lifestyle
• Liver or kidney disease
• Co-administration of other substances

References

1. Klaassen, C.D. (Ed.) - Casarett and Doull's Toxicology: The Basic Science of Poisons. 9th Edition. McGraw-Hill Education, 2019.
2. Guengerich, F.P. - Mechanisms of cytochrome P450-catalyzed oxidations. ACS Catalysis, 2018. PubMed PMID: 30505600.
3. Wilkinson, G.R. - Drug metabolism and variability among patients in drug response. New England Journal of Medicine, 2005. DOI: 10.1056/NEJMra032424.